Quick Answer
Aquestive Therapeutics, Inc. reported Net Income Loss of -$83.78 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -89.8% in Net Income Loss from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$1.46 million | Q2 2017: -$5.90 million | Q3 2017: $8.45 million | Q4 2017: -$10.04 million | Q1 2018: $4.10 million | Q2 2018: -$36.49 million | Q3 2018: -$15.04 million | Q4 2018: -$13.94 million | Q1 2019: -$14.73 million | Q2 2019: -$20.47 million | Q3 2019: -$18.41 million | Q4 2019: -$12.64 million | Q1 2020: -$16.53 million | Q2 2020: -$2.33 million | Q3 2020: -$16.55 million | Q4 2020: -$20.37 million | Q1 2021: -$14.67 million | Q2 2021: -$12.37 million | Q3 2021: -$14.56 million | Q1 2022: -$13.22 million | Q2 2022: -$16.30 million | Q3 2022: -$12.54 million | Q1 2023: $8.07 million | Q2 2023: -$5.79 million | Q3 2023: -$2.04 million | Q1 2024: -$12.83 million | Q2 2024: -$2.75 million | Q3 2024: -$11.51 million | Q1 2025: -$22.93 million | Q2 2025: -$13.55 million | Q3 2025: -$15.45 million.
- Over the full 9 years of available data (2017 to 2025), Aquestive Therapeutics, Inc.'s Net Income Loss has declined by 836.9%.
- Historical annual values: Fiscal year 2025: -$83.78 million | Fiscal year 2024: -$44.14 million | Fiscal year 2023: -$7.87 million | Fiscal year 2022: -$54.41 million | Fiscal year 2021: -$70.54 million | Fiscal year 2020: -$55.78 million | Fiscal year 2019: -$66.25 million | Fiscal year 2018: -$61.38 million | Fiscal year 2017: -$8.94 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: